|
|||||
|
|
CD30-positive lymphoproliferative disorders—An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre |
|
| Authors: | Friyana K Bhabha MBBS FACD Christopher McCormack MBBS FACD Belinda A Campbell MBBS MMed FRANZCR Stephen Lade MBBS FRCPA Odette Buelens RN BN PGDipNur |
| Institution: | 1. Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;2. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia;3. Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;4. Nurse Practitioner, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;5. Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia |
| Abstract: | The CD30-postive lymphoproliferative disorders, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, account for up to 30% of all cutaneous T-cell lymphomas (CTCLs) and are the second most common form of CTCLs after mycosis fungoides. Both conditions differ in their clinical presentations; however, they share the expression of the CD30 antigen as a common immunophenotypic hallmark. There is a wide spectrum of management options depending on factors such as extent of disease, staging and treatment tolerability. This Clinical Practice Statement is reflective of the current clinical practice in Australia. |
| Keywords: | CD30 lymphoproliferative disorders cutaneous T cell lymphoma lymphomatoid papulosis primary cutaneous anaplastic large cell lymphoma |